Bone marrow necrosis in neuroendocrine tumor of the thymus

Ducourneau, Benoît; Hemar, Claire

doi:10.1002/ccr3.1728

Cited by 1 publication

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common site of metastasis in NENs is the liver (40%-93%) followed by bone (12%-20%) and lung (10.8%)[ 16 ]. Metastatic NEN in bone marrow is extremely rare and most reported cases are NECs[ 4 - 8 , 11 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…Both the patients received multiple cycles of chemotherapy; however, no effect was observed[ 4 , 5 ]. Another bone marrow metastatic NEC case was offered best supportive care; however, the patient died 2 wk after diagnosis[ 8 ]. PRRT is recommended in advanced NEN patients with positive somatostatin receptors (SSTRs)[ 7 ].…”

Section: Discussionmentioning

confidence: 99%

“…It is reported that 30% of BMN cases are found in solid tumors[ 28 ]. As previously mentioned, a patient with BMN caused by a thymic NET died 2 wk after diagnosis[ 8 ], and another case of BMN secondary to gastric cancer passed away shortly after hospitalization[ 31 ]. Thus, the prognosis of patients suffering from solid tumors with BMN is significantly worse than that of patients with malignancies alone.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Bone marrow metastatic neuroendocrine carcinoma with unknown primary site: A case report and review of the literature

Shi¹,

Deng²,

Jin³

2022

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Metastatic neuroendocrine carcinoma (NEC) of bone marrow is uncommon. Here, we report a case of bone marrow metastatic NEC with an unknown primary site. CASE SUMMARY A 73-year-old Chinese woman was admitted to our hospital because marked chest distress and asthma lasting 1 d on March 18, 2018. She was initially diagnosed with pulmonary infection, cardiac insufficiency, thrombocytopenia and severe anemia. Following treatment with antibiotic therapy, diuresis and blood transfusion, the patient’s symptoms greatly improved. After bone marrow examinations, the patient was diagnosed with bone marrow metastatic NEC, bone marrow necrosis (BMN) and secondary myelofibrosis (MF). Further imaging workup did not show the primary tumor, we presumed that the primary site might regress spontaneously or merely be unexplored due to lack of positron emission tomography with gallium peptide. Everolimus (10 mg/d) was added to the treatment and the best supportive and symptomatic therapies were also administered. Unfortunately, the patient’s condition continued to deteriorate and she died on May 15, 2018. CONCLUSION Bone marrow invasion of NEC is rare and our patient who suffered from bone marrow metastatic NEC as well as secondary BMN and MF had an extremely poor prognosis. Bone marrow biopsy plays an important role in the diagnosis of solid tumors invading bone marrow.

show abstract